166 related articles for article (PubMed ID: 12364468)
1. Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.
Danila DC; Zhang X; Zhou Y; Haidar JN; Klibanski A
J Clin Endocrinol Metab; 2002 Oct; 87(10):4741-6. PubMed ID: 12364468
[TBL] [Abstract][Full Text] [Related]
2. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling.
Zhou Y; Sun H; Danila DC; Johnson SR; Sigai DP; Zhang X; Klibanski A
Mol Endocrinol; 2000 Dec; 14(12):2066-75. PubMed ID: 11117535
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
Alexander JM; Bikkal HA; Zervas NT; Laws ER; Klibanski A
J Clin Endocrinol Metab; 1996 Feb; 81(2):783-90. PubMed ID: 8636304
[TBL] [Abstract][Full Text] [Related]
4. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells.
Bernard DJ; Lee KB; Santos MM
Reprod Biol Endocrinol; 2006 Oct; 4():52. PubMed ID: 17040568
[TBL] [Abstract][Full Text] [Related]
5. Identification of a functional binding site for activin on the type I receptor ALK4.
Harrison CA; Gray PC; Koerber SC; Fischer W; Vale W
J Biol Chem; 2003 Jun; 278(23):21129-35. PubMed ID: 12665502
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.
Kaivo-Oja N; Mottershead DG; Mazerbourg S; Myllymaa S; Duprat S; Gilchrist RB; Groome NP; Hsueh AJ; Ritvos O
J Clin Endocrinol Metab; 2005 Jan; 90(1):271-8. PubMed ID: 15483083
[TBL] [Abstract][Full Text] [Related]
7. A human pituitary tumor-derived folliculostellate cell line.
Danila DC; Zhang X; Zhou Y; Dickersin GR; Fletcher JA; Hedley-Whyte ET; Selig MK; Johnson SR; Klibanski A
J Clin Endocrinol Metab; 2000 Mar; 85(3):1180-7. PubMed ID: 10720059
[TBL] [Abstract][Full Text] [Related]
8. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
9. Activin A Increases Human Trophoblast Invasion by Inducing SNAIL-Mediated MMP2 Up-Regulation Through ALK4.
Li Y; Klausen C; Zhu H; Leung PC
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1415-27. PubMed ID: 26305619
[TBL] [Abstract][Full Text] [Related]
10. Activin A and activin receptors in the human thyroid: a link to the female predominance of goiter?
Schulte KM; Jonas C; Krebs R; Röher HD
Horm Metab Res; 2000 Oct; 32(10):390-400. PubMed ID: 11069203
[TBL] [Abstract][Full Text] [Related]
11. Activin stimulates CYP19A gene expression in human ovarian granulosa cell-like KGN cells via the Smad2 signaling pathway.
Nomura M; Sakamoto R; Morinaga H; Wang L; Mukasa C; Takayanagi R
Biochem Biophys Res Commun; 2013 Jul; 436(3):443-8. PubMed ID: 23747729
[TBL] [Abstract][Full Text] [Related]
12. Activin isoforms signal through type I receptor serine/threonine kinase ALK7.
Tsuchida K; Nakatani M; Yamakawa N; Hashimoto O; Hasegawa Y; Sugino H
Mol Cell Endocrinol; 2004 May; 220(1-2):59-65. PubMed ID: 15196700
[TBL] [Abstract][Full Text] [Related]
13. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
14. Activin effects on neoplastic proliferation of human pituitary tumors.
Danila DC; Inder WJ; Zhang X; Alexander JM; Swearingen B; Hedley-Whyte ET; Klibanski A
J Clin Endocrinol Metab; 2000 Mar; 85(3):1009-15. PubMed ID: 10720031
[TBL] [Abstract][Full Text] [Related]
15. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells.
Bilezikjian LM; Corrigan AZ; Blount AL; Chen Y; Vale WW
Endocrinology; 2001 Mar; 142(3):1065-72. PubMed ID: 11181520
[TBL] [Abstract][Full Text] [Related]
16. Activin A and activin receptors in thyroid cancer.
Schulte KM; Jonas C; Krebs R; Röher HD
Thyroid; 2001 Jan; 11(1):3-14. PubMed ID: 11272093
[TBL] [Abstract][Full Text] [Related]
17. Activin signaling through type IB activin receptor stimulates aromatase activity in the ovarian granulosa cell-like human granulosa (KGN) cells.
Mukasa C; Nomura M; Tanaka T; Tanaka K; Nishi Y; Okabe T; Goto K; Yanase T; Nawata H
Endocrinology; 2003 Apr; 144(4):1603-11. PubMed ID: 12639945
[TBL] [Abstract][Full Text] [Related]
18. Expression of activin/inhibin receptor and binding protein genes and regulation of activin/inhibin peptide secretion in human adrenocortical cells.
Vänttinen T; Kuulasmaa T; Liu J; Voutilainen R
J Clin Endocrinol Metab; 2002 Sep; 87(9):4257-63. PubMed ID: 12213882
[TBL] [Abstract][Full Text] [Related]
19. Novel action of activin and bone morphogenetic protein in regulating aldosterone production by human adrenocortical cells.
Suzuki J; Otsuka F; Inagaki K; Takeda M; Ogura T; Makino H
Endocrinology; 2004 Feb; 145(2):639-49. PubMed ID: 14592955
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
